ROCKET PHARMACEUTICALS, INC.

# Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals is a biopharmaceutical company incorporated in Delaware and listed on the Nasdaq. The company focuses on developing gene therapy and gene-modified cell therapy treatments for rare genetic diseases and cancers. Its pipeline includes programs targeting conditions such as fanconi anemia, pyruvate kinase deficiency, and other inherited disorders where gene modification offers potential therapeutic benefit.

The company's approach centers on utilizing lentiviral vector technology to deliver functional genes into patient cells, with the goal of providing durable or curative treatments. Rocket Pharmaceuticals' programs are primarily in clinical development stages, with therapies designed to address underserved patient populations in orphan disease segments. The company operates across multiple therapeutic areas, including inherited bone marrow failure syndromes and metabolic disorders.

Specific details regarding current employee count, annualized revenue figures, and precise geographic distribution of operations are not provided in the available data. As a clinical-stage biopharmaceutical company, Rocket Pharmaceuticals operates primarily within the United States, with development and regulatory activities concentrated in major pharmaceutical research hubs. The company's business model is characteristic of development-stage firms, relying on capital financing and eventual commercialization of approved therapies to generate revenue.